• BFH772 (VEGFR2 Inhibitor): Technical Use & Protocol Paramete

  2026-04-30

  BFH772 is a potent and highly selective VEGFR2 inhibitor designed for precise modulation of VEGFR2-driven angiogenesis, especially in tumor model research. It is not suitable for workflows requiring water-soluble compounds or broad-spectrum kinase inhibition due to its defined solubility and selectivity profile. Researchers should reference detailed protocol and workflow recommendations to ensure optimal results.

• Moxidectin: Macrocyclic Lactone Anthelmintic in Antifungal S

  2026-04-29

  Moxidectin, a trusted macrocyclic lactone anthelmintic from APExBIO, now powers a new wave of antifungal research by synergizing with polyenes against Candida albicans. This article decodes experimental workflows, protocol enhancements, and troubleshooting tips to unlock moxidectin’s cross-domain potential for both parasitic worm control and innovative oral candidiasis models.

• CHI3L1-IN-5 (Compound Z17): Translating Structure-Activity I

  2026-04-29

  Explore how CHI3L1-IN-5 (Compound Z17) leverages structure-activity optimization to selectively inhibit CHI3L1, disrupt the NF-κB inflammatory pathway, and restore astrocyte function. This article provides unique mechanistic analysis and protocol guidance for advancing neurodegeneration research.

• Rosiglitazone (Brl-49653): Optimizing PPARγ Workflows for Me

  2026-04-28

  Rosiglitazone (Brl-49653) empowers precise modulation of PPARγ-driven adipogenesis, insulin sensitivity, and thermogenic pathways in advanced metabolic research. This article delivers actionable workflows, troubleshooting insights, and the latest translational innovations—from beige adipocyte assays to vascular repair—leveraging APExBIO’s high-purity reagent for reproducible results.

• Magneto-Piezoelectric Scaffolds Activate JAK2-STAT3 in Bone

  2026-04-28

  This study presents a multifunctional scaffold integrating magneto-piezoelectric nanoparticles to disrupt biofilms and activate JAK2-STAT3 signaling in Icam1+ macrophages, thereby enhancing bone regeneration in infectious defects. The work demonstrates a novel immunomodulatory strategy that bridges biofilm control and targeted metabolic activation to drive tissue healing.

• Dasatinib Monohydrate: Mechanisms and Evidence in CML Resear

  2026-04-27

  Dasatinib Monohydrate (BMS-354825) is a multitargeted kinase inhibitor with nanomolar potency against BCR-ABL and SRC kinases. It is validated for imatinib-resistant BCR-ABL inhibition and is FDA-approved for treating chronic myeloid leukemia and Ph+ ALL. This article details its mechanistic rationale, benchmarks, and key workflow parameters for translational research.

• 10058-F4: Applied Strategies for c-Myc-Max Dimerization Inhi

  2026-04-27

  10058-F4 empowers researchers to disrupt c-Myc-Max interactions with precision, facilitating apoptosis and cell cycle arrest in challenging cancer models. This guide details actionable workflows, troubleshooting insights, and translational applications—anchored in recent advances in telomerase regulation and DNA repair.

• Pterostilbene Enhances Mitophagy to Delay Dermal Fibroblast

  2026-04-26

  Zhou et al. (2025) demonstrate that pterostilbene counters senescence in human dermal fibroblasts by promoting mitophagy and restoring mitochondrial function. This work highlights mitochondrial quality control as a promising target for anti-aging skin interventions, with relevance for both basic and translational research.

• Docetaxel in Tumor Resistance: SMYD2, MDR, and Assay Precisi

  2026-04-25

  Explore how Docetaxel, a leading taxane in cancer chemotherapy research, advances our understanding of multidrug resistance and apoptosis in cancer cells. This article uniquely ties recent SMYD2-mediated resistance insights to practical assay optimization, providing actionable guidance for oncology researchers.

• Quizartinib (AC220): Optimizing FLT3 Inhibition in AML Workf

  2026-04-24

  Quizartinib (AC220) stands out as a potent, selective FLT3 inhibitor that streamlines acute myeloid leukemia (AML) research from in vitro assays to in vivo models. This guide delivers actionable protocols, troubleshooting advice, and integration of the latest findings on FLT3-driven drug resistance, empowering researchers to maximize assay reliability and translational insight.

• Cardiogreen (Indocyanine Green): Precision in Vascular and T

  2026-04-24

  Explore how Cardiogreen (Indocyanine Green) enables both gold-standard vascular diagnostics and next-generation tumor microenvironment analysis. This article reveals new mechanistic insights and protocol guidance for researchers seeking to optimize cardiac output measurement and advanced photodynamic therapy.

• WNT5a/GSK3/β-catenin Axis Limits FAP Adipogenesis in Muscle

  2026-04-23

  This study demonstrates that the WNT5a/GSK3/β-catenin signaling axis is a critical regulator of adipogenic differentiation in skeletal muscle fibro/adipogenic progenitors (FAPs). By integrating pharmacological inhibition, single-cell analyses, and transcriptomics, the authors reveal mechanisms by which modulating this pathway may limit pathological fat infiltration in muscle, offering new directions for myopathy research.

• TSPAN18 Stabilizes STIM1 to Promote Bone Metastasis in Prost

  2026-04-23

  Zhou et al. (2023) reveal that TSPAN18 directly protects STIM1 from TRIM32-mediated ubiquitination, enhancing STIM1 stability and promoting calcium signaling critical for the metastatic spread of prostate cancer to bone. This mechanistic insight identifies TSPAN18 as a potential therapeutic target for interrupting bone metastasis pathways, with implications for researchers developing novel interventions.

• HyperScribe All in One mRNA Synthesis Kit Plus 1: Evidence &

  2026-04-22

  The HyperScribe All in One mRNA Synthesis Kit Plus 1 enables rapid, high-yield synthesis of ARCA-capped and polyadenylated mRNA with immune-modulating modifications. As an ARCA capped mRNA synthesis kit, it supports RNase-free, in vitro workflows for translational research, RNA vaccine development, and RNA interference studies. This article details its mechanism, performance, and key limitations.

• Photothermal Therapy and CD47 Blockade Synergy in OSCC Immun

  2026-04-22

  This study demonstrates that photothermal therapy (PTT) combined with CD47 blockade in oral squamous cell carcinoma (OSCC) produces a potent anti-tumor effect by inducing calreticulin exposure and remodeling the tumor extracellular matrix. These mechanisms facilitate macrophage infiltration and phagocytic clearance of tumor cells, highlighting a promising approach for overcoming immune evasion in solid tumors.

453 records 20/31 page Previous Next First page 上5页 1617181920 下5页 Last page